The National Medical Products Administration approved Dupixent as an add-on maintenance treatment for adults with ...

Ohtuvayre (ensifentrine) is a first-in-class selective dual inhibitor of the enzymes phosphodiesterase three and phosphodiesterase 4 (“PDE3 and PDE4”) that combines bronchodilator and non-steroidal ...

Key Takeaways Regeneron and Sanofi shares edged higher Friday after their drug to treat chronic obstructive pulmonary disease ...

The FDA approved dupilumab today as the first biologic treatment for patients with uncontrolled chronic obstructive pulmonary ...

Approval follows EU approval of Dupixent for adults with COPD with raised blood eosinophils, and is based on two landmark Phase 3 trials showing ...

After more than a decade without any therapeutic advancements in chronic obstructive pulmonary disorder (COPD), people with ...

Changes in people’s voices recoded on a smartphone can signal a serious flare up in symptoms of chronic obstructive pulmonary ...

While smoking is a key risk factor for chronic obstructive pulmonary disease (COPD), significant prevalence also exists among ...

健康风险增加:COPD合并高血压患者不但会出现高血压疾病、COPD疾病自身引起的健康问题,还会导致中风、心脏病发作等发生率明显升高,甚至会引起较为严重的并发症问题,以上并发症在对患者生活质量产生影响的同时,还会对患者的生命安全产生威胁。

Regeneron stock XX on XX after the company won FDA approval for Dupixent in chronic obstructive pulmonary disease, or COPD.

The FDA approved dupilumab (Dupixent) as the first biologic treatment for adults with chronic obstructive pulmonary disease ...

Regeneron and Sanofi on Friday said the green light covers Dupixent as an add-on maintenance treatment in certain adults with uncontrolled chronic obstructive pulmonary disease, or COPD, and makes ...